Editor in Chief Dr KK Aggarwal, Padma Shri Awardee
Scientists develop stamp-sized wearable device to monitor COVID-19 patients
AWashington: Researchers have developed a stamp-sized device, comprising a suite of sensors, including ones that record body temperature and blood oxygen levels, an advance that can be used to catch early signs and symptoms of COVID-19, and help monitor patients as the illness progresses. The scientists, including John A. Rogers from Northwestern University in the US, said they have tested the novel device on more than 50 physicians, rehabilitation specialists, and patients at the country's Shirley Ryan AbilityLab and at the Northwestern Memorial Hospital.
According to an editorial, published in the journal Science Advances, the sticker-like medical device, which is of the size of a postage stamp, is soft, flexible, and sits just below the suprasternal notch -- the visible dip at the base of the throat.
CMAAO Coronavirus Facts and Myth Buster: Colchicine
962: Is Colchicine a Promising Agent in COVID-19 Treatment?
Medscape excerpts: Colchicine is an anti-inflammatory drug commonly used to treat gout and rheumatic disease. The drug may be a promising treatment for COVID-19, suggests a randomized, open-label trial.,The Greek Study in the Effects of Colchicine in COVID-19 Complications Prevention (GRECCO-19) randomized 105 patients with COVID-19 to receive either the standard of care or the standard of care plus colchicine for 3 weeks. Among patients in the colchicine group, the time to clinical deterioration was found to improve, although there were no significant differences between the groups in terms of cardiac and inflammatory biomarkers.
The key seems to lie on the drug’s anti-inflammatory properties combined with an antithrombogenic effect that was noted in the present cohort and has also been reported in the literature. The study was published online June 24 in JAMA Network Open.
World Covid Meter 3rd July: 213 Countries Affected
Cases: 1M: April 2, 2M April 15, 3M April 27, 4M May 8, 5M May 20, 6M May 30, 7M June 7, 8M June 15, 9M June 22, 10M June29
Ground Zero: Wuhan - in live animal market or cafeteria for animal pathogens: 10th January; Total cases are based on RT PCR, 67% sensitivity
Doubling time India 20 days, USA 33 days, Brazil 13 days, Russia 18 days, Spain 47 days, UK 35 days, Italy 55 days, France 49 days, Turkey 37 days
Likely minimum deaths (523947 + 58134 x 15 == 8720) = 532667,Coronavirus Cases: 10,982,236,Deaths: 523,947,Recovered: 6,139,611,ACTIVE CASES: 4,318,678
Sewa is the best dharma
Offering help is the best service to the humanity. As per Sikhism, Sewa (unconditional service), Simran (meditation) and Satsang (company of good people) constitute the trio to acquire happiness and spiritual health. In Sikhism, Sewa is the main path for acquiring spiritualism. In Gurudwara, one even offers Sewa by cleaning the shoes of others or by cleaning the entry paths to any Gurudwara.
Offering help covers all the paths of being a Satyugi, i.e., truthfulness, unconditional hard work, purity of mind and finally, Daya and Daan. When you offer help, you always do it in a positive state of mind and it involves hard work, mercy and charity.
Video of The day
COVID 19 can have both viral and inflammatory responses
Healthcare News Monitor
The Indian pharmaceutical industry has enough stock of raw materials, and the delays in clearing Chinese-origin shipments by customs across ports will not disrupt production.
Domestic drugmakers, which import about two-thirds of their active pharmaceutical ingredients (APIs) from China, witnessed severe supply disruptions since March due to the covid-19-led lockdown in Wuhan, and other pharma hubs.
Subsequently, Indian drug makers stocked up enough raw material to safeguard against any supply disruption from China, a top executive of a pharma major said, requesting anonymity. The existing stock with most pharma companies will last two to three months, while larger firms have at least four months of inventory for certain active pharmaceutical ingredient (APIs), he added.
The Indian Express
Zydus -a part of the Cadila health care group said they have indigenously developed its plasmid DNA vaccine candidate for COVID 19 – called ZyCOV-D. Pre clinical trials have been completed and they have received the go ahead for human clinical trials. The company said that the vaccine had been developed at its vaccine technology centre at Ahmedabad
The company’s chairman, Pankaj Patel, told The Indian Express that they had undertaken different animal studies since March, conducted toxicity studies in two different animal species, and found that the vaccine was safe.
“We have successfully completed the preclinical phase and received permission from Drug Controller General of India-Central Drugs Standard Control Organisation (CDSCO) to initiate Phase I/II human clinical trials in India,” Patel said.
The Indian Express
“I am having breathing issues. All my symptoms are of corona… I will be 100% positive,” said Dr Abhishek Bhayana (26) to his elder brother Aman (31) on Thursday morning, hours before he passed away following complaints of chest congestion and breathlessness.
,He had tested negative twice for Covid-19.,Working as a junior resident doctor at Delhi’s Maulana Azad Institute for Dental Sciences (MAIDS), Abhishek was posted in the department of oral surgery of the dental institute.(Follow coronavirus Delhi LIVE UPDATES here)
,He secured rank 21 in the AIIMS MDS exam, and travelled to Rohtak on June 26 to appear for counselling.
Four days after India’s first indigenous vaccine candidate for Covid-19 was granted approval for human clinical trials by the drug regulator, the Indian Council of Medical Research on Thursday said that it wanted to “launch the vaccine for public health use latest by August 15”.
On July 2, the council’s director-general Balram Bhargava wrote to the 12 institutions participating in the trial to “fast-track all approvals”, adding that participants on whom the vaccine would be tested should be enrolled “no later than July 7”.
,“Non-compliance will be viewed very seriously,” the letter warned, adding that the vaccine was “the top-most priority” of the government.
,The vaccine candidate, named Covaxin, has been jointly developed by the Hyderabad-based private company Bharat Biotech and the ICMR. It was approved for human trial on June 29. In effect, the ICMR is saying it would release a vaccine for human use in less than two months of it being approved for trial – a timeline unheard of anywhere in the world.